Late effects of radiation therapy include:

Mucositis, Enteritis, Pneumonitis, Somatic mutations

Mucositis, Enteritis, Nausea and vomiting, Pneumonitis

Enteritis, Nausea and vomiting, Pneumonitis, Somatic mutations

Mucositis, Nausea and vomiting, Pneumonitis, Somatic mutations

Which of the following malignant diseases of children has the best prognosis -

Primitive neuroectodermal tumor

Screening for colorectal cancer is recommended when?

Early diagnosis can change the disease course due to effective treatment.

The condition has a low case fatality rate.

Diagnostic tools are not available.

There is no effective treatment available.

Late Effects of Cancer Treatment for NEET-PG: High-Yield Pediatrics Lessons

Intro & Risks - Aftermath Aces

Late Effects: Health problems appearing ≥5 years after cancer treatment ends, or earlier if persistent/progressive.
Key Risk Factors:
- Younger age at diagnosis (↑ vulnerability).
- Genetic predisposition (e.g., Li-Fraumeni).
- Treatment type & intensity:
  - Chemotherapy (agent, cumulative dose).
  - Radiotherapy (site, dose, volume).
  - Surgery, HSCT.
- Primary cancer type.
📌 ACES for Risks: Age, Cancer type/Chemo, Exposure (Radiation), Susceptibility (Genetic).

⭐ Childhood cancer survivors: >5x risk of severe chronic conditions by age 50 vs. siblings.

Childhood Cancer Survivors: Risk of Late Effects oka

Systemic Effects - Organ Hit List

A summary of common late effects by organ system:

Organ System	Key Causal Agents/Tx	Major Late Effects
Cardiac	Anthracyclines (Doxorubicin), Cyclophosphamide, Chest RT	Cardiomyopathy (dose-dependent), CHF, Arrhythmias, CAD, Valvular disease, Pericarditis. Monitor with ECHO.
Pulmonary	Bleomycin, Busulfan, Carmustine (BCNU), Chest RT	Pneumonitis, Pulmonary fibrosis. Monitor with PFTs.
Endocrine	Cranial RT, Neck RT, Alkylating agents, TBI	GH deficiency (most common), Hypothyroidism, Gonadal failure (infertility, POI), Adrenal insufficiency, Diabetes.
Renal	Cisplatin (📌 "splats" kidneys/ears), Carboplatin, Ifosfamide, High-dose MTX, RT	↓GFR, Tubular damage (Fanconi - Ifosfamide), Glomerulopathy, Hypertension. Monitor U/A, Creatinine.
Neurocognitive	Cranial RT (dose & age-dependent), IT MTX/Ara-C	↓IQ, Learning disabilities, Memory/attention deficits, Leukoencephalopathy. Vinca alkaloids, Cisplatin: Peripheral neuropathy.
Musculoskeletal	Corticosteroids, Methotrexate, RT	Osteoporosis, Avascular necrosis (AVN), Growth retardation, Scoliosis, Soft tissue fibrosis.
Gastrointestinal	Abdominal RT, Anthracyclines, Vincristine	Chronic enteritis, Malabsorption, Strictures, Esophagitis, Hepatic fibrosis/veno-occlusive disease (VOD).
Second Cancers	Alkylating agents, Etoposide, RT	AML/MDS (peak 5-10 yrs), Solid tumors (e.g., sarcoma, breast, thyroid; peak >10 yrs).

Late effects of pediatric cancer treatment by diagnosis

Malignancies & Mind - Double Trouble

Second Malignant Neoplasms (SMNs):
- Most common solid SMN: Thyroid cancer (post-radiation), Breast cancer.
- Most common hematological SMN: Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS) (post-alkylating agents, etoposide).
- Risk factors: Genetic predisposition (e.g., Li-Fraumeni), type/dose of therapy (radiation, alkylating agents, etoposide), younger age at treatment.
- Screening: Lifelong surveillance based on primary cancer and treatment received.
Psychosocial Impact:
- ↑ Risk: Anxiety, depression, PTSD, social isolation, academic difficulties, unemployment.
- Body image issues, neurocognitive deficits (chemo brain).
- Need for long-term psychological support & counseling.

⭐ Alkylating agents (e.g., cyclophosphamide) and epipodophyllotoxins (e.g., etoposide) are highly associated with therapy-related AML/MDS, often occurring 5-10 years post-treatment.

📌 Alkylating Agents & Etoposide cause AML/MDS Eventually (AAE-AAE).

Surveillance & Care - Watch & Ward

Goal: Early detection & management of late effects; improve quality of life (QoL).
Risk-Stratified Care: Tailored by diagnosis, treatment (chemo, RT, surgery), age.
COG Guidelines: Standard for screening (echo, PFTs, mammograms).
Survivor Clinics: Multidisciplinary team (oncology, endocrine, cardio, psych).
Interventions:
- Regular exams & history.
- Organ-specific screening.
- Vaccinations (key for immunosuppressed).
- Lifestyle counseling (diet, exercise, no smoking).
- Psychosocial support.

⭐ Hodgkin Lymphoma survivors (mantle RT): annual mammography + breast MRI from age 25 or 8 yrs post-RT (whichever later), not beyond age 40.

High‑Yield Points - ⚡ Biggest Takeaways

Secondary Malignancies: Significant risk of AML/MDS (alkylating agents, etoposide) and solid tumors post-radiation.

Cardiotoxicity: Anthracyclines (e.g., doxorubicin) induce dose-dependent cardiomyopathy; monitor closely.

Organ Toxicities: Bleomycin (pulmonary fibrosis); Cisplatin (nephrotoxicity, ototoxicity).

Endocrinopathies: Common include hypothyroidism, GH deficiency (cranial radiation), and gonadal dysfunction.

Neurocognitive Impairment: Frequent after cranial radiation and high-dose/intrathecal methotrexate.

Ifosfamide: Associated with hemorrhagic cystitis (prevent with MESNA) and renal Fanconi syndrome.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play